http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020208082-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f4d86235703b3e2a1cb10b98722d80d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd65351eab2c0f2d452fa21140abc831 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-19 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00 |
| filingDate | 2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79e43ef61f15a839cd59dad0df98083c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac5a872b1d96b83834ce0046f3fedb84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d21304fc7870600a1752b27b7dacbf2 |
| publicationDate | 2020-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020208082-A1 |
| titleOfInvention | Method for treating cmv related diseases |
| abstract | The present invention relates to the treatment of CMV related diseases. In a rat model of CMV infection of the developing brain in utero, the inventors recently detected prominent infection of brain immune cells and early neuroimmune defects at the cellular and molecular levels. Severe postnatal phenotypes reminiscent of the human disease (e.g. epileptic seizures, altered sensorimotor development) the inventors observed in the first postnatal weeks. At the molecular level, they now have investigated the pathophysiological role of the chemokine rl29, encoded by the rat CMV genome (used as a proof of concept) and that showed very early RNA expression in RCMV-infected fetal brains. Co-infection experiments of the developing brain in utero with wild-type (wt) RCMV and with its mutant RCMV counterpart encoding a dominant- negative r129 isoform dramatically rescued the severe postnatal phenotypes caused by wt RCMV alone. Furthermore, sequential infection with the two viruses, starting with in utero injection at E14 of RCMV encoding the dominant-negative r129 isoform, then followed 24h apart by in utero injection at E15 of the wt RCMV, also led to dramatic rescue of the postnatal phenotypes. Importantly, injection of only the RCMV encoding the dominant-negative r129 isoform did not lead to any of the postnatal phenotypes observed with the wt RCMV. Thus, the use of an inhibitor of EIL128 (e.g. the use of a dominant-negative, inhibitory isoform of EIL128), the human CMV (hCMV) analogue of r129, will have the same benefit on CMV related diseases. Thus, the present invention relates to an ETL128 inhibitor for use in the treatment and prevention of CMV related diseases in a subject in need thereof. |
| priorityDate | 2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 139.